학술논문
Post-acute symptoms 3-15 months after COVID-19 among unvaccinated and vaccinated individuals with a breakthrough infection.
Document Type
Academic Journal
Author
Brunvoll SH; Department of Microbiology, Oslo University Hospital, Pb 4950, 0424 Oslo, Norway. Electronic address: shbrunvoll@gmail.com.; Nygaard AB; Department of Microbiology, Oslo University Hospital, Pb 4950, 0424 Oslo, Norway. Electronic address: anders.b.nygaard@gmail.com.; Fagerland MW; Oslo Centre for Biostatistics and Epidemiology, Research Support Services, Oslo University Hospital, Pb 4950, 0424 Oslo, Norway. Electronic address: m.w.fagerland@medisin.uio.no.; Holland P; Department of Microbiology, Oslo University Hospital, Pb 4950, 0424 Oslo, Norway. Electronic address: petter.holland@gmail.com.; Ellingjord-Dale M; Department of Microbiology, Oslo University Hospital, Pb 4950, 0424 Oslo, Norway. Electronic address: mellingjord@hotmail.com.; Dahl JA; Department of Microbiology, Oslo University Hospital, Pb 4950, 0424 Oslo, Norway. Electronic address: j.a.dahl@medisin.uio.no.; Søraas A; Department of Microbiology, Oslo University Hospital, Pb 4950, 0424 Oslo, Norway. Electronic address: arne@meg.no.
Source
Publisher: Elsevier Country of Publication: Canada NLM ID: 9610933 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1878-3511 (Electronic) Linking ISSN: 12019712 NLM ISO Abbreviation: Int J Infect Dis Subsets: MEDLINE
Subject
Language
English
Abstract
Objective: We aimed to describe post-acute sequelae of SARS-CoV-2 infection (PASC) related symptoms 3-15 months after a positive test in SARS-CoV-2 unvaccinated and vaccinated participants with a breakthrough infection.
Methods: Participants of the Norwegian COVID-19 cohort, without a positive SARS-CoV-2 test, completed a questionnaire about PASC-related symptoms between November 2020 and January 2021. About a year later, a second questionnaire (which also included the Everyday Memory Questionnaire [EMQ]-13) was completed by the same participants, most still without a positive SARS-CoV-2 test, but also by unvaccinated and vaccinated participants with a positive test 3-15 months before the questionnaire. Laboratory-confirmed SARS-CoV-2 status (positive or negative swab test determined by reverse transcriptase quantitative polymerase chain reaction) at the time of completing the questionnaire was ascertained from the Mandatory Norwegian Surveillance System for Communicable Diseases.
Results: No differences were found in the self-reported PASC symptoms, dyspnea, fatigue, smell/taste changes, concentration problems, or the EMQ-13 score between unvaccinated and vaccinated participants 3-15 months after the positive test. Fewer memory problems were reported among vaccinated than unvaccinated participants.
Conclusion: SARS-CoV-2 vaccines offer minor protection against PASC symptoms, although fewer memory problems were reported among the vaccinated than the unvaccinated participants.
Competing Interests: Declaration of competing interest The authors have no competing interests to declare.
(Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
Methods: Participants of the Norwegian COVID-19 cohort, without a positive SARS-CoV-2 test, completed a questionnaire about PASC-related symptoms between November 2020 and January 2021. About a year later, a second questionnaire (which also included the Everyday Memory Questionnaire [EMQ]-13) was completed by the same participants, most still without a positive SARS-CoV-2 test, but also by unvaccinated and vaccinated participants with a positive test 3-15 months before the questionnaire. Laboratory-confirmed SARS-CoV-2 status (positive or negative swab test determined by reverse transcriptase quantitative polymerase chain reaction) at the time of completing the questionnaire was ascertained from the Mandatory Norwegian Surveillance System for Communicable Diseases.
Results: No differences were found in the self-reported PASC symptoms, dyspnea, fatigue, smell/taste changes, concentration problems, or the EMQ-13 score between unvaccinated and vaccinated participants 3-15 months after the positive test. Fewer memory problems were reported among vaccinated than unvaccinated participants.
Conclusion: SARS-CoV-2 vaccines offer minor protection against PASC symptoms, although fewer memory problems were reported among the vaccinated than the unvaccinated participants.
Competing Interests: Declaration of competing interest The authors have no competing interests to declare.
(Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved.)